Focus and Purpose of the paper

HIV has become a very contentious and controversial illness for many around the world. HIV has become a societal health concern as it continues to grow as a result of increased sexual activity of individuals around the world. In the United States alone roughly 1.5 million people have HIV. Even more alarming is that roughly 20% of these individuals do not know they have the virus. This partially explains the steady rise in infections rates around the world, as not only are more individuals have unprotected sexual intercourse, many are going undiagnosed due to lack of proper healthcare infrastructure and treatment. In addition, preventative mechanism, used to help mitigate the spread of HIV has been rendered moot due to poor planning and healthcare infrastructure. This only exacerbates the steady growth of HIV that is occurring around the world. Currently, there are 34 million HIV positive people worldwide. Roughly 66% of these individuals or 24 million reside in sub-Sahara Africa. In African alone, roughly 1.2 million individuals die every year due to HIV infections (Hollingsworth, 2018).

HIV is a virus that attacks the immune system of body, rendering it useless against other bacteria and infections. Even more alarming, if HIV is not treated, it can eventually lead to AIDS, which has very severe consequences for the individual. If left untreated, these consequences can include death. Currently there is no effective cure for HIV. Once it is contracted, the individual has it for life. Thankfully, through medication such as Apretude, HIV can be controlled. Those with HIV can not only live healthy lives, they can do so productivity due to advancements in treatment options. The common symptoms of HIV are fever, chills, rash, night sweats, fatigue and mouth ulcers. As noted in the introduction, it is critical for individual to get tested if they contract these symptoms so that they can properly mitigate an HIV diagnosis (HIV and AIDS, 2020).

HIV has three primary stages. Stage 1 is termed Acute HIV infection. Stage 2 is the chronic HIV infection, and Stage 3 is AIDS. A summary of each stage along with common characteristics is found in Table 1 below.

Table 1 Stages of HIV

Stage

Common Characteristics

States 1 Acute HIV Infection

Very high contagion risk

Flu-like symptoms

Possible to not experience any symptoms at all

Testing is very important during this phase.

Stage 2 Chronic HIV Infection

Stage is termed asymptomatic HIV infection or clinical latency

The virus is active but reproduces at a very low level

Period can last a decade or longer without treatment

Transmition of the virus is very easy during this phase

Treatment is very important during this phase to prevent going into stage 3

Stage 3 AIDS

Most severe phase of HIV

Heavily damages immune system

Higher susceptibility for infection and adverse side effects

Highly infectious

Without treatment, people will survive for only three years.

Here, the new drug Apretude, can help significantly alleviate the side effects of HIV. The treatment guidelines for HIV first revolve around testing. It is important for those who are sexually active to conduct regular testing for HIV. Next, it is important to communicate properly with partners in the invent an individual is HIV positive. In addition, it is important to adopt evidence-based prevention strategies based on the latest research available. Finally, it is important to develop community-based resources that can help prevent further spread of the virus to others. This illness can be fully treated through abstinence (Kuhar 2020).

Patient Introduction

The patient will be treated using the new medication noted above. In this circumstance the patient suffers from both Asthma and Hypertension. This has adverse impacts on the individual as it can potentially impact how the drug is administered and the cadence of the treatment. With these conditions that patient will take the oral cabotegravier for four weeks. After the four weeks an assessment will be conducted to determine the bodies response

Introduction of New Medication

The mechanisms of action or indication for usage is a single-does vial containing 600 mg/3 mL (200 mg/mL) of cabotegravir as a white to light pink, free-flowing, extended-release injectable suspension. The kit contains a syringe, vial adapter, and needle for intramuscular injection. As it relates to injection the ventrogluteal is the recommended option. In addition the dorsolateral region is also an acceptable administration approach. Here,...

…exacerbating the affordability issue of drugs in the United States. This has particularly negative ramifications for the drug and treatment as consumers may be unable to afford the option. With consumer less likely to adopt the treatment option, HIV can continue to spread to at-risk communities such as African and other parts of the United States. Costs also enter into the equation as treatment require multiple doses on a consistent basis. Currently. The treatment option is a single pill that is administered orally or through injection. However, the treatment must occur at least once a month for it to be effective. As a result, clients looking to leverage the drug must do so on a consistent basis to utilize the benefits it provides. This again can adversely impact the overall cost equation as becomes more expensive to engage it preventative HIV treatment (Balter, 2020).

This is an important element when prescribing the drug as set expectations for the client in an honest and ethical manner. When prescribing the drug, even to patients that have insurance, it isimportant to recognize how treatment may impact their overall financial standing. This allows patients to make better informed decisions while also protecting their health.

Role of APN in providing care for this patient

The role of the APN is critical to providing proper care to the patient. Here, the APN is an important information conduit for the patient. For one, they are going to be interacting with the patient on a much more consistent and intimate basis. They will also be interacting with the patient with administration tasks related to medical records and other sensitive information. As it relates to the rationale for determining if the medication should be part of the therapeutic regimen, the APN should first communicate all of the benefits and negative aspects of the treatment to the patient. These aspects will include cost, side effects, benefits, and overall administration. The patient should then take this information and determine if the treatment is right for them with guidance from qualified medical personnel. In addition, the patient and medical professional must consider their own personal issues relates to hypertension and obesity into account.

To conclude,…